Immutep TACTI-002 Eftilagimod Alpha Phase II Trial Results 2023

Presentation of final data from the TACTI-002 Phase II trial evaluating eftilagimod alpha (soluble LAG-3) combined with pembrolizumab in second-line metastatic NSCLC patients who are resistant to PD-1/PD-L1 inhibitors. Eftilagimod alpha is an MHC-Class II agonist that activates antigen-presenting cells to enhance CD8 T-cell responses and potentially overcome immunotherapy resistance. Trial design includes primary endpoint of objective response rate per iRECIST with secondary endpoints of progression-free survival, overall survival, safety, and biomarker assessments.